Literature DB >> 29528393

Novel insights into SMALED2: BICD2 mutations increase microtubule stability and cause defects in axonal and NMJ development.

Lilian A Martinez Carrera1,2,3, Elke Gabriel3, Colin D Donohoe2,4, Irmgard Hölker1,2,3, Aruljothi Mariappan3, Markus Storbeck1,2,3, Mirka Uhlirova2,4, Jay Gopalakrishnan3, Brunhilde Wirth1,2,3,5.   

Abstract

Bicaudal D2 (BICD2) encodes a highly conserved motor adaptor protein that regulates the dynein-dynactin complex in different cellular processes. Heterozygous mutations in BICD2 cause autosomal dominant lower extremity-predominant spinal muscular atrophy-2 (SMALED2). Although, various BICD2 mutations have been shown to alter interactions with different binding partners or the integrity of the Golgi apparatus, the specific pathological effects of BICD2 mutations underlying SMALED2 remain elusive. Here, we show that the fibroblasts derived from individuals with SMALED2 exhibit stable microtubules. Importantly, this effect was observed regardless of where the BICD2 mutation is located, which unifies the most likely cellular mechanism affecting microtubules. Significantly, overexpression of SMALED2-causing BICD2 mutations in the disease-relevant cell type, motor neurons, also results in an increased microtubule stability which is accompanied by axonal aberrations such as collateral branching and overgrowth. To study the pathological consequences of BICD2 mutations in vivo, and to address the controversial debate whether two of these mutations are neuron or muscle specific, we generated the first Drosophila model of SMALED2. Strikingly, neuron-specific expression of BICD2 mutants resulted in reduced neuromuscular junction size in larvae and impaired locomotion of adult flies. In contrast, expressing BICD2 mutations in muscles had no obvious effect on motor function, supporting a primarily neurological etiology of the disease. Thus, our findings contribute to the better understanding of SMALED2 pathology by providing evidence for a common pathomechanism of BICD2 mutations that increase microtubule stability in motor neurons leading to increased axonal branching and to impaired neuromuscular junction development.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29528393     DOI: 10.1093/hmg/ddy086

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  6 in total

Review 1.  Gene expression in stress urinary incontinence: a systematic review.

Authors:  Ilaha Isali; Amr Mahran; Ahmad O Khalifa; David Sheyn; Mandy Neudecker; Arshna Qureshi; Britt Conroy; Fredrick R Schumacher; Adonis K Hijaz; Sherif A El-Nashar
Journal:  Int Urogynecol J       Date:  2019-07-16       Impact factor: 2.894

Review 2.  Revisiting the role of mitochondria in spinal muscular atrophy.

Authors:  Rachel James; Helena Chaytow; Leire M Ledahawsky; Thomas H Gillingwater
Journal:  Cell Mol Life Sci       Date:  2021-04-05       Impact factor: 9.261

3.  Impairment in dynein-mediated nuclear translocation by BICD2 C-terminal truncation leads to neuronal migration defect and human brain malformation.

Authors:  Meng-Han Tsai; Haw-Yuan Cheng; Fang-Shin Nian; Chen Liu; Nian-Hsin Chao; Kuo-Liang Chiang; Shu-Fang Chen; Jin-Wu Tsai
Journal:  Acta Neuropathol Commun       Date:  2020-07-14       Impact factor: 7.801

Review 4.  Defects in Axonal Transport in Inherited Neuropathies.

Authors:  Danique Beijer; Angela Sisto; Jonas Van Lent; Jonathan Baets; Vincent Timmerman
Journal:  J Neuromuscul Dis       Date:  2019

5.  Loss of BICD2 in muscle drives motor neuron loss in a developmental form of spinal muscular atrophy.

Authors:  Alexander M Rossor; James N Sleigh; Michael Groves; Francesco Muntoni; Mary M Reilly; Casper C Hoogenraad; Giampietro Schiavo
Journal:  Acta Neuropathol Commun       Date:  2020-03-17       Impact factor: 7.801

6.  Dynein activating adaptor BICD2 controls radial migration of upper-layer cortical neurons in vivo.

Authors:  Lena Will; Sybren Portegies; Jasper van Schelt; Merel van Luyk; Dick Jaarsma; Casper C Hoogenraad
Journal:  Acta Neuropathol Commun       Date:  2019-10-26       Impact factor: 7.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.